𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Enzyme replacement therapy and intraepidermal innervation density in Fabry disease

✍ Scribed by Raphael Schiffmann; Peter Hauer; Barbara Freeman; Markus Ries; Leland J. C. Scott; Michael Polydefkis; Roscoe O. Brady; Justin C. McArthur; Kathryn Wagner

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
88 KB
Volume
34
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We prospectively evaluated the effect of enzyme replacement therapy (ERT) on the intraepidermal nerve fiber density (IENFD) and thermal threshold in patients with Fabry disease, an X‐linked disorder associated with a painful small‐fiber neuropathy and decreased linear IENFD in a length‐dependent pattern. Twenty‐five hemizygous male patients with Fabry disease were enrolled in a 6‐month, randomized, placebo‐controlled ERT trial of 0.2 mg/kg of α‐galactosidase A (agalsidase‐alfa) every 2 weeks followed by an additional 12 months of open‐label ERT for both populations. IENFD and thermal threshold were measured in the distal thigh at baseline, 6 months, and 18 months from initiation of the trial. We found no significant difference in IENFD between the treatment groups at 6 months. After an additional year of ERT, there was a significant reduction in IENFD in the patient group as a whole, attributable to the declining glomerular filtration rate. Thermal thresholds remained unchanged. We conclude that epidermal nerve fiber regeneration, as measured in the distal thigh, does not occur in this patient population after 12–18 months of ERT. Muscle Nerve, 2006

📜 SIMILAR VOLUMES

Enzyme replacement therapy induces T-cel
Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease
✍ Miklos Banati; Zsolt Hosszu; Anita Trauninger; Laszlo Szereday; Zsolt Illes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

## Abstract ## Introduction: Enzyme replacement therapy (ERT) in ultra‐orphan Pompe disease generates anti‐rhGAA antibodies, which may interfere with efficacy. ## Methods: rhGAA‐specific T‐cell responses were examined at different time‐points in 6 Hungarian patients treated with rhGAA and compar

Replacement therapy for inherited enzyme
Replacement therapy for inherited enzyme deficiency: Liver orthotopic transplantation in Niemann-Pick disease type A
✍ Daloze, Pierre ;Delvin, Edgard E. ;Glorieux, Francis H. ;Corman, Jacques L. ;Bet 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 729 KB

## Abstract Liver homotransplantation was attempted as replacement therapy in a 2‐year‐old patient with near total absence of sphingomyelinase activity typical of Niemann‐Pick disease type A. Satisfactory function of the graft was observed until the death of the recipient from respiratory complicat

Correction of neutrophil chemotaxis defe
Correction of neutrophil chemotaxis defect in patients with gaucher disease by low-dose enzyme replacement therapy
✍ Dr. A. Zimran; A. Abrahamov; M. Aker; Y. Matzner 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 1 views

We have recently described a chemotactic defect in severely afflicted Gaucher disease patients. Two of the patients were treated with low-dose intravenous enzyme replacement (Ceredase). Marked improvement in their hematological status, organomegaly, and growth was observed. In addition, their chemot